The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
In blind studies the effects of a new alpha-glucosidase inhibitor (BAY g 5421) were tested in normal weight and overweight male volunteers after oral application of 75, 150, or 300 mg of BAY g 5421 or placebo per os before three standardized main meals of one day. Before and three hours after each meal blood glucose, serum insulin, and serum triglyceride levels were determined. In addition, safety studies were performed. BAY g 5421 induced a statistically significant, in part dose-dependent inhibition of the postprandial increase of blood glucose- and serum insulin levels. The reduction of the postprandial increase of serum triglyceride levels was variable. Routine blood chemistry and hematology tests have revealed no adverse side effects; but the application of the drug was frequently associated with intestinal effects, such as flatulence and diarrhea, which were substrate (carbohydrate) and, in part, dose-dependent.
D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004032:Diet; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D009765:Obesity / Q000378:metabolism; D009844:Oligosaccharides / Q000009:adverse effects / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood*; D014312:Trisaccharides / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D009844:Oligosaccharides; D014280:Triglycerides; D014312:Trisaccharides; D005959:Glucosidases